U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Size, Share & Industry Analysis, By Technique (Lateral Flow Immunoassay, Agglutination Test, Flow-through Test, Molecular Diagnostics, and Others), By Disease (Human Immunodeficiency Virus (HIV), Hepatitis B Virus, Pneumonia/Streptococcus Associated Infections, Respiratory Syncytial Virus (RSV), Influenza, Clostridium Difficile Infections (CDI), Hepatitis C Virus, Tuberculosis, COVID-19, and Others), By End-user (Hospitals, Physician’s Offices, Urgent Care & Retail Clinics, and Others), and Country Forecast, 2024-2032

Last Updated: December 01, 2025 | Format: PDF | Report ID: FBI109902

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Prevalence of Key Infectious Diseases, U.S., 2023
2. Technological Advancements in Infectious Disease Point-of-Care (POC) Diagnostics
3. Overview of Initiatives for Infectious Disease Point-of-Care (POC) Diagnostics, U.S.
4. Pricing Analysis of Various Infectious Disease Point-of-Care (POC) Diagnostics, By Key Companies
5. Analysis of Product Features of Key Infectious Disease Point-of-Care (POC) Diagnostics, By Key Companies
6. New Product Launches, By Key Players
7. Recent Industry Developments - Mergers & Acquisitions
8. Impact of COVID-19 on the Market
U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Technique
  1. Lateral Flow Immunoassay (LFIA)
  2. Agglutination Test
  3. Flow-through test
  4. Molecular Diagnostics
  5. Others
2. Market Analysis, Insights and Forecast – By Disease
  1. Human Immunodeficiency Virus (HIV)
  2. Hepatitis B Virus
  3. Pneumonia/Streptococcus Associated Infections
  4. Respiratory Syncytial Virus (RSV)
  5. Influenza
  6. Clostridium Difficile Infections (CDI)
  7. Hepatitis C Virus
  8. Methicillin-resistant Staphylococcus Aureus (MRSA)
  9. Tuberculosis
  10. COVID-19
  11. Others
3. Market Analysis, Insights and Forecast – By End-user
  1. Hospitals
  2. Physician’s Offices
  3. Urgent Care & Retail Clinics
  4. Homecare Settings
  5. Nursing Homes
  6. Others
Competitive Analysis
1. U.S. Market Share Analysis (2023)
2. Company Profiles
  1. F. Hoffmann-La Roche Ltd.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  2. Thermo Fisher Scientific Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  3. Abbott Laboratories
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  4. Quest Diagnostics Incorporated
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  5. BD
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  6. bioMérieux SA
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  7. Cardinal Health, Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  8. Cepheid
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  9. Trinity Biotech
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  10. Quidel Corporation
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  11. Bio-Rad Laboratories Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Prevalence of Key Infectious Diseases, U.S., 2023
2. Technological Advancements in Infectious Disease Point-of-Care (POC) Diagnostics
3. Overview of Initiatives for Infectious Disease Point-of-Care (POC) Diagnostics, U.S.
4. Pricing Analysis of Various Infectious Disease Point-of-Care (POC) Diagnostics, By Key Companies
5. Analysis of Product Features of Key Infectious Disease Point-of-Care (POC) Diagnostics, By Key Companies
6. New Product Launches, By Key Players
7. Recent Industry Developments - Mergers & Acquisitions
8. Impact of COVID-19 on the Market
U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Technique
  1. Lateral Flow Immunoassay (LFIA)
  2. Agglutination Test
  3. Flow-through test
  4. Molecular Diagnostics
  5. Others
2. Market Analysis, Insights and Forecast – By Disease
  1. Human Immunodeficiency Virus (HIV)
  2. Hepatitis B Virus
  3. Pneumonia/Streptococcus Associated Infections
  4. Respiratory Syncytial Virus (RSV)
  5. Influenza
  6. Clostridium Difficile Infections (CDI)
  7. Hepatitis C Virus
  8. Methicillin-resistant Staphylococcus Aureus (MRSA)
  9. Tuberculosis
  10. COVID-19
  11. Others
3. Market Analysis, Insights and Forecast – By End-user
  1. Hospitals
  2. Physician’s Offices
  3. Urgent Care & Retail Clinics
  4. Homecare Settings
  5. Nursing Homes
  6. Others
Competitive Analysis
1. U.S. Market Share Analysis (2023)
2. Company Profiles
  1. F. Hoffmann-La Roche Ltd.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  2. Thermo Fisher Scientific Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  3. Abbott Laboratories
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  4. Quest Diagnostics Incorporated
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  5. BD
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  6. bioMérieux SA
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  7. Cardinal Health, Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  8. Cepheid
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  9. Trinity Biotech
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  10. Quidel Corporation
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  11. Bio-Rad Laboratories Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)

Read Less

List of Figures

Figure 1: U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Revenue Breakdown (USD million, %) by Technique, 2023 & 2032

Figure 2: U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Value Share (%), by Technique, 2023 & 2032

Figure 3: U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Value Share (%), by Disease, 2023 & 2032

Figure 4: U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Value Share (%), by End-user, 2023 & 2032

Figure 5: U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Share (%), By Company, 2023

List of Tables

Table 1: U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Revenue (USD million) Forecast, by Technique, 2019-2032

Table 2: U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Revenue (USD million) Forecast, by Disease, 2019-2032

Table 3: U.S. Infectious Disease Point-of-care (POC) Diagnostics Market Revenue (USD million) Forecast, by End-user, 2019-2032

STUDY PERIOD: 2019-2032
BASE YEAR: 2023
HISTORICAL DATA: 2019-2022
NO OF PAGES: 70

Buy Now

Download Free Sample

Security Code

Growth Advisory Services

Clients

Related Reports

Get In Touch With Us

US +1 833 909 2966 ( Toll Free )

UK +44 808 502 0280 ( Toll Free )

+91 744 740 1245 (APAC)
sales@fortunebusinessinsights.com